The Biotech Analyst Group

Disclaimer. Our content is intended for informational purpose only. Our conclusion may be wrong and may cause losses. Do your own research before making any investment.

Coegin Pharma: Phase I/II AK study on track. Danish Medical Agency approve application to start the study. Coegin Pharma follows plan, start in August 2021. coeginpharma.com/media/pressmed…

Synact: follow up conf. 7th July on positive data from the phase 2a trial of AP1189 in Covid-19 infected patients. mb.cision.com/Main/14427/337…

Aegirbio: secured capacity to produce 9 million Covid diagnostic test per month, starting in August. aegirbio.com/news/aegirbio-…

2cureX: news.cision.com/2curex/r/2cure…

Please read our disclaimer before you invest. We may be completely wrong and any investment based on our conclusions may cause severe losses.

@xGuineapig It is actually their wording, straight from the release, so not our wording. We get your point.

@BiotechAnalystG You mean decrease, I assume? As in an improvement? It would be bad if the time was prolonged/increased

SynAct Pharma: Patients treated with AP1189 recovered respiratory function on average 3.5 days quicker than did placebo treated patients, a 35% increase in recovery time. synactpharma.com/en/synact-phar…

Chordate Medical: Clinical evaluation of Chordates K.O.S treatment for rhinitis in public hospitals in Saudi Arabia now approved chordate.com/investor-relat…

CombiGene and Neurochase begin work to optimize the administration of CG01 combigene.com/en/news-and-re…

Aegirbio: Progress according to plan. Test order worth (revenue) 100 MSEK, with potential to generate (revenue) 200 MSEK per month.

@petejmasters Don't know, not member of the fb-group. Bullish engulfing yesterday, PAS today have a conservative target of 60 SEK, should the Covid vaccine reach market the upside is even higher. In the ball park range we estimated to. However, we believe >100 SEK if vaccine is approved.

ExpreS2ion: gap closure today if you are into TA. Bullish engulfing candle in the making? Start phase II, financing sorted and phase I/II data upcoming.

Aptahem: aptahem.com/en/aptahems-co…

Scandion Oncology: positive interim results from phase II.

Combigene: Ready to start GMP production CG01 mfn.se/a/combigene/gm…

Coegin Pharma: probably a good buy opportunity today.

@Success_X1 Kancera: According to CEO, results from the Covid-19 study will be presented when the study is completed, hence 90 days after last patient is treated. Presentation of results after 7-days is cancelled due to lack of resources at hospitals and lab. Complete data in Q4 2021

@Success_X1 no, still waiting

Portfolio update: We look forward to follow our new position in Coegin Pharma. Two spinouts and start of phase I/II in August, study completed this year. In our opinion, the two spinouts are not priced in at all in current market cap (likely value when launched 100-200 MSEK).

Kancera: According to CEO, results from the Covid-19 study will be presented when the study is completed, hence 90 days after last patient is treated. Presentation of results after 7-days is cancelled due to lack of resources at hospitals and lab. Complete data in Q4 2021

Coegin Pharma: Technically the price is building up momentum nicely, indicating higher highs.

@Success_X1 agree, poor communication

@BiotechAnalystG Not okey to ignore the stockholders 🤨